Literature DB >> 15624375

Facial telangiectasia-an unusual complication of neonatal lupus erythematosus: report of one case.

Sheng-Chieh Lin1, Shyh-Dar Shyur, Jiunn-Yi Wu, Li-Hsin Huang.   

Abstract

Neonatal lupus erythematosus (NLE) is an uncommon passive autoimmune disease caused by transplacental passage of anti-Ro/SSA and/or anti-La/SSB or anti-U1RNP maternal autoantibodies. Common clinical manifestations include cutaneous lupus lesions, cardiac disease, notably congenital heart block, hematologic abnormalities, and hepatobiliary disease. The cutaneous lesions of NLE are usually transient, disappearing about six months after birth when maternal antibodies disappear from the infant's circulation. Persistent telangiectasia is a rare complication of NLE. We report a 3-year-old female who had cutaneous lupus with persistent facial telangiectasias over the frontal area. She was diagnosed with NLE at 2 months of age. Her findings then included cutaneous lupus, hemolytic anemia, a high titer of antinuclear antibodies (1: 640) with a speckled pattern, positive anti-Ro/SSA and anti-La/SSB antibodies, and absence of anti-dsDNA antibodies. Her mother had systemic lupus erythematosus with the presence of high titer of antinuclear antibodies (1: 1260) with a speckled pattern and positive anti-Ro/SSA and anti-La/SSB antibodies. The child's cutaneous lupus and hemolytic anemia disappeared at 6 months of age, but the telangiectasia persisted.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15624375

Source DB:  PubMed          Journal:  Acta Paediatr Taiwan        ISSN: 1608-8115


  2 in total

Review 1.  Neonatal Lupus: What We Have Learned and Current Approaches to Care.

Authors:  Marisa S Klein-Gitelman
Journal:  Curr Rheumatol Rep       Date:  2016-09       Impact factor: 4.592

2.  Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.

Authors:  Julie Barsalou; Nathalie Costedoat-Chalumeau; Adey Berhanu; Cesar Fors-Nieves; Ummara Shah; Patrick Brown; Carl A Laskin; Nathalie Morel; Kateri Levesque; Jill P Buyon; Earl D Silverman; Peter M Izmirly
Journal:  Ann Rheum Dis       Date:  2018-10-08       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.